Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
12268 studies found for:    "Carcinoma"
Show Display Options
Rank Status Study
1 Active, not recruiting CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Conditions: Carcinoma, Basal Cell;   Carcinoma, Squamous Cell;   Skin Neoplasms;   Skin Diseases;   Neoplasms, Basal Cell;   Neoplasms, Squamous Cell;   Carcinoma
Interventions: Drug: 5-fluorouracil;   Drug: Placebo, vehicle control
2 Active, not recruiting Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: sorafenib tosylate;   Drug: cisplatin;   Drug: docetaxel;   Other: Correlative Studies
3 Terminated
Has Results
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
Conditions: Carcinoma, Squamous Cell;   Carcinoma, Adenosquamous;   Carcinoma, Large Cell;   Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CP-751,871 (Figitumumab);   Drug: Carboplatin;   Drug: Paclitaxel
4 Recruiting Study of aNK (Activated NK-92, Formerly Neukoplast) Infusions in Patients With Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)
Conditions: Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma
Intervention: Biological: aNK
5 Completed Oral Rigosertib for Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinoma;   Anal Squamous Cell Carcinoma;   Lung Squamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Esophageal Squamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Penile Squamous Cell Carcinoma
Intervention: Drug: rigosertib
6 Active, not recruiting A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
Conditions: Carcinoma, Renal Cell;   Renal Cell Carcinoma of Papillary Histology;   Renal Cell Carcinoma With Clear Cell Histology;   Renal Cell Carcinoma With Non-Clear Cell Histology
Intervention: Drug: AGS-16C3F
7 Active, not recruiting ADXS11-001 High Dose HPV+ Cervical Cancer
Conditions: Effects of Immunotherapy;   Metastatic/Recurrent Cervical Cancer;   Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Cervical Small Cell Carcinoma;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Intervention: Biological: ADXS11-001
8 Unknown  Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma
Conditions: Carcinoma, Giant Cell;   Carcinoma, Non-Small-Cell Lung;   Lung Cancer
Intervention:
9 Completed A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Conditions: HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma;   HER2 + Breast Cancer;   HER2 + Gastric Cancer;   Squamous Cell Carcinoma of Head and Neck;   Esophageal Squamous Cell Carcinoma
Intervention: Drug: LJM716
10 Active, not recruiting Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma
Conditions: Carcinoma;   Carcinoma Renal Cell;   Kidney Neoplasms;   Kidney Diseases;   Chemokines
Intervention: Biological: Biological sample
11 Recruiting A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Conditions: Gastric Adenocarcinoma;   Adenocarcinoma of the Gastroesophageal Junction;   Non-small Cell Lung Cancer;   Carcinoma, Transitional Cell;   Biliary Tract Cancer
Interventions: Drug: Ramucirumab;   Drug: Pembrolizumab
12 Completed
Has Results
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Conditions: Neuroendocrine Carcinoma;   Islet Cell Carcinoma
Interventions: Drug: RAD001;   Drug: Octreotide Depot
13 Completed
Has Results
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
Conditions: Head and Neck Neoplasms;   Pheochromocytoma;   Colorectal Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Renal Cell
Intervention: Drug: Fostamatinib disodium
14 Completed ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
Conditions: Non-Small-Cell Lung Carcinoma;   Renal Cell Carcinoma;   Pancreatic Cancer
Intervention: Drug: ABR-217620
15 Completed Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Conditions: Carcinoma of Urinary Tract;   Urethral Carcinoma;   Carcinoma of Ureter;   Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel;   Biological: Ramucirumab DP;   Biological: IMC-18F1
16 Terminated VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features
Conditions: Carcinoma, Non-Small-Cell Lung;   Adenocarcinoma, Bronchiolo-Alveolar
Intervention: Drug: VELCADE
17 Recruiting MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Drug: MLN0128
18 Completed Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck
Conditions: Squamous Cell Carcinoma;   Carcinoma of Head and/or Neck
Interventions: Drug: Taxotere;   Drug: Cisplatin;   Drug: 5-Fluorouracil;   Drug: Leucovorin
19 Completed Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Conditions: Gastrin-Producing Neuroendocrine Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Paraganglioma;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Biological: Cixutumumab;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Drug: Octreotide Acetate;   Other: Pharmacological Study
20 Active, not recruiting A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx
Conditions: Dysplasia;   Carcinoma of the Oral Cavity;   Carcinoma of the Oropharynx
Intervention: Drug: HPPH

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years